Folate Receptor Alpha (Fra) Targeted Therapy Competitor Analysis Report 2025: Next Generation Cell Therapy Modalities And Radiopharmaceuticals Are Advancing In The Pipeline

(MENAFN- GlobeNewsWire - Nasdaq) Folate receptor alpha (FRα) presents strong market opportunities as a validated target, especially in ovarian and lung adenocarcinomas. Potential growth lies in next-gen ADCs, bispecific antibodies, cell therapies, and radiopharmaceuticals, driven by enhanced effector functions and broader therapeutic windows.

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets's offering.
This competitive intelligence report about Folate Receptor alpha (FRa) Targeted Therapies provides a competitor evaluation in the field of product candidates in research and development targeting Folate Receptor alpha (FRa). The report lists FRa -targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of FRa-targeted therapies by drug modality.
Folate receptor alpha (FRa) is a cell surface GPI-anchored protein overexpressed in several solid tumors with highest prevalence in ovarian cancer and lung adenocarcinoma but restricted expression in normal tissues. An antibody drug conjugate (ADC) with a microtubule inhibitor (MTI) payload recently received accelerated approval from the FDA for FRa-expressing platinum-resistant ovarian cancer. Thus, folate receptor alpha is a clinically validated target with commercial potential as evidenced by sales of more than US$ 500 mln in its second full year of commercialization after first approval in 2022. Furthermore, the FRa-targeted ADC was the main reason for an equity value of US$ 10 bln when the originator company Immunogen was acquired by Abbvie.
Folate receptor alpha holds great promise as a target for next generation improved drug candidates based on drug modalities known to enhance effector function and/or to broaden the therapeutic window. Among FRa-targeted drug modalities in use for next generation therapy candidates are ADCs with novel targeting moieties and linker/payload technologies as well as novel small molecule drug conjugates.

Furthermore, next generation cell therapy modalities and radiopharmaceuticals are advancing in the pipeline. And T-cell or NK cell engaging bispecific antibodies are further drug modalities applied to folate receptor alpha therapies.
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN27112025004107003653ID1110406305